The invocation of “national defense” to justify increased domestic production of glyphosate isn’t a policy shift so much as a calculated risk assessment by President Trump, betting that economic security for agricultural interests outweighs the potential political cost of alienating a key voting bloc. The February 18th executive order, ostensibly aimed at reducing reliance on foreign supply chains for the herbicide Roundup, immediately triggered a backlash from the “Make America Healthy Again” (MAHA) movement – the very constituency that helped propel Robert F. Kennedy Jr. into the role of Health and Human Services Secretary. This isn’t a simple contradiction; it’s a demonstration of how readily stated principles can be sacrificed at the altar of established economic and political power.
The immediate beneficiaries are clear: Bayer, Monsanto’s parent company and the sole domestic producer of glyphosate, and the American agricultural industry, which relies heavily on the herbicide for efficient crop production. The order, leveraging the 1950 Defense Production Act, effectively guarantees a market for glyphosate, a chemical facing increasing scrutiny over its potential health risks. The timing is particularly advantageous for Bayer, which recently offered a $7.25 billion settlement to resolve cancer claims linked to Roundup. Less visible, but equally significant, is the $1 million donation Trump’s inaugural committee received from Bayer – a detail that underscores the financial ties underpinning this decision. Conversely, the immediate losers are the MAHA voters, particularly those who crossed party lines to support Trump based on promises of addressing pesticide concerns. Activists like Zen Honeycutt of Moms Across America are framing the order as a “glyphosate love letter” and a “deep betrayal,” potentially jeopardizing their support in crucial upcoming elections where control of Congress is at stake.
Drawn from USA Today.
This situation echoes historical precedents where economic interests have overridden public health concerns, often justified under the guise of national security. The early 20th-century debates surrounding leaded gasoline offer a stark parallel. Despite mounting evidence of its neurotoxic effects, the lead industry successfully lobbied to maintain its market share, framing lead as essential for engine performance and, by extension, national transportation. Similarly, the decades-long resistance to regulating asbestos, despite clear links to mesothelioma, was fueled by the economic power of the asbestos industry and its arguments about the material’s importance to construction and infrastructure. In both cases, the long-term health consequences were downplayed in favor of short-term economic gains. The current glyphosate situation isn’t unique; it’s a continuation of this pattern, albeit with a new layer of political complexity.
The appointment of Robert F. Kennedy Jr. as HHS Secretary initially signaled a potential shift in policy. Kennedy’s history of litigating against Monsanto and his vocal criticism of glyphosate had made him a hero to the MAHA movement. However, the executive order reveals a tension between Kennedy’s personal convictions and the broader political calculus within the Trump administration. The White House’s attempt to frame the order as simply strengthening national security and ending reliance on foreign imports feels disingenuous, particularly given the readily available alternatives to glyphosate, including regenerative agriculture practices. Kelly Ryerson, known as @GlyphosateGirl on social media, succinctly captures the sentiment: “This administration is not significantly different from any previous administration in serving the chemical industry's interests over human health.” The contradiction is further highlighted by the Solicitor General’s recent decision to support efforts limiting Monsanto’s legal liability, and the failed congressional funding bills that would have shielded chemical companies from pesticide-related lawsuits – all occurring after Kennedy’s appointment.
The political chess move to watch next isn’t whether Trump will reverse the executive order – though MAHA influencers are actively pushing for that outcome. It’s whether Robert F. Kennedy Jr. will publicly challenge the administration’s decision. His silence, or a tepid defense of the order, will signal a complete capitulation to the political realities of his position. A forceful rebuke, however, could fracture the coalition that brought Trump to power and open a significant rift within the administration, potentially reshaping the landscape of the upcoming elections. The question isn’t just about glyphosate; it’s about the limits of compromise and the price of political expediency.
